Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 3/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21249304 | 0.87 | LMNA (0.58) | HDAC8HDAC6LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL7647660 | 0.86 | NPSR1 (0.65) | LMNAKMT2AMEN1HDAC3ANO1 | |
| SCHEMBL21095553 | 0.86 | HDAC8 (0.66) | HDAC8HDAC6NR1H4LMNAKMT2A | |
| SCHEMBL10120025 | 0.84 | HDAC8 (0.59) | HDAC8HDAC6ACHENR1H4KMT2A | |
| SCHEMBL12201883 | 0.84 | HDAC8 (0.77) | HDAC8HDAC6ACHENR1H4KMT2A | |
| SCHEMBL13698098 | 0.82 | ACHE (0.60) | HDAC8HDAC6ACHENR1H4KMT2A | |
| SCHEMBL22524754 | 0.80 | LMNA (0.56) | LMNAKMT2AMEN1SMN1; SMN2CYP2C19 | |
| SCHEMBL159046 | 0.80 | LMNA (0.52) | LMNAKMT2AMEN1CYP2C19ANO1 | |
| SCHEMBL13701766 | 0.80 | S100B (0.60) | LMNAKMT2AMEN1SMN1; SMN2CYP2C19 | |
| SCHEMBL159047 | 0.80 | KDM4E (0.61) | LMNAKMT2AMEN1CYP2C19ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10716801-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190183913-A1 | Silanol Based Therapeutic Payloads | BLINKBIO INC (US) | 2019-06-20 | — | — | US | disclosed |
| US-10301255-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10293053-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | BLINKBIO INC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8513421-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301255-B2 | Hepatitis B antiviral agents | HAVCR2, ZC3HAV1, SLC10A1 | HDAC8 1574/4885HDAC6 2426/4885ACHE 4469/4885 |
| US-20190183913-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | HDAC8 501/4885HDAC6 586/4885ACHE 4785/4885 |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | HDAC8 1574/4885HDAC6 2426/4885ACHE 4469/4885 |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | HDAC8 13/4885HDAC6 1/4885ACHE 3602/4885 |
| US-10716801-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | HDAC8 501/4885HDAC6 586/4885ACHE 4785/4885 |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | HDAC8 501/4885HDAC6 586/4885ACHE 4785/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | HDAC8 19/4885HDAC6 1/4885ACHE 1149/4885 |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | HDAC8 11/4885HDAC6 1/4885ACHE 3502/4885 |
| US-10293053-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | HDAC8 501/4885HDAC6 586/4885ACHE 4785/4885 |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | HDAC8 13/4885HDAC6 1/4885ACHE 3488/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | HDAC8 20/4885HDAC6 1/4885ACHE 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.